T1	Observation 11 33	enrolled in this study
T2	Temporal 0 10	Previously
R1	Has_temporal Arg1:T1 Arg2:T2	
T3	Procedure 86 104	surgical procedure
T4	Temporal 74 85	Concomitant
R2	Has_temporal Arg1:T3 Arg2:T4	
T5	Procedure 116 120	CABG
T6	Qualifier 105 115	other than
R3	Has_qualifier Arg1:T5 Arg2:T6	
R4	AND Arg1:T3 Arg2:T5	
T7	Procedure 122 145	Anticoagulant treatment
T8	Temporal 146 165	after the operation
T9	Reference_point 152 165	the operation
T10	Procedure 156 165	operation
R5	multi Arg1:T9 Arg2:T10	
R6	Has_index Arg1:T8 Arg2:T9	
R7	Has_temporal Arg1:T7 Arg2:T8	
T11	Drug 172 180	warfarin
T12	Drug 182 208	direct thrombin inhibitors
T13	Drug 210 220	dabigatran
R8	Subsumes Arg1:T12 Arg2:T13	
T14	Drug 223 237	FXa inhibitors
T15	Drug 239 250	rivaroxaban
T16	Drug 252 260	apixaban
T17	Drug 262 269	heparin
T18	Drug 271 299	low-molecular weight heparin
T19	Drug 301 313	fondaparinux
*	OR T15 T16 T17 T18 T19
T20	Scope 239 313	rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux
R9	Subsumes Arg1:T14 Arg2:T20	
*	OR T11 T12 T14
T21	Scope 172 313	warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux
R10	Subsumes Arg1:T7 Arg2:T21	
T22	Observation 316 325	Discharge
T23	Visit 335 353	operating hospital
T24	Visit 360 363	ICU
T25	Qualifier 367 374	another
T26	Visit 375 383	hospital
R11	Has_qualifier Arg1:T26 Arg2:T25	
T27	Scope 360 383	ICU at another hospital
R12	AND Arg1:T22 Arg2:T23	
R13	Has_scope Arg1:T22 Arg2:T27	
T28	Condition 385 394	Pregnancy
T29	Condition 398 407	lactation
T30	Condition 430 446	contraindication
T31	Condition 415 426	intolerance
T32	Drug 450 460	ticagrelor
T33	Drug 464 467	ASA
*	OR T32 T33
*	OR T31 T30
T34	Scope 415 446	intolerance or contraindication
T35	Scope 450 467	ticagrelor or ASA
R14	Has_scope Arg1:T34 Arg2:T35	
T36	Condition 473 481	disorder
T37	Qualifier 487 521	may interfere with drug absorption
R15	Has_qualifier Arg1:T36 Arg2:T37	
T38	Condition 548 571	coronary artery disease
T39	Negation 537 547	other than
R16	Has_negation Arg1:T38 Arg2:T39	
T40	Condition 527 536	condition
R17	AND Arg1:T40 Arg2:T38	
T41	Observation 579 594	life expectancy
T42	Value 595 605	<12 months
R18	Has_value Arg1:T41 Arg2:T42	
R19	Has_context Arg1:T40 Arg2:T41	
T43	Condition 613 634	chronic liver disease
T44	Condition 636 649	renal disease
T45	Procedure 660 668	dialysis
T46	Condition 672 689	bleeding disorder
T47	Mood 650 659	requiring
R20	Has_mood Arg1:T45 Arg2:T47	
*	OR T44 T43 T46
R21	AND Arg1:T44 Arg2:T45	
T48	Condition 691 716	Atrioventricular block II
T49	Condition 691 713;721 724	Atrioventricular block III
T50	Negation 737 744	without
T51	Device 745 754	pacemaker
R22	Has_negation Arg1:T51 Arg2:T50	
*	OR T49 T48
T52	Condition 781 806	dual antiplatelet therapy
T53	Procedure 820 838	stent implantation
T54	Temporal 813 819	recent
R23	Has_temporal Arg1:T53 Arg2:T54	
T55	Condition 766 776	indication
R24	AND Arg1:T55 Arg2:T52	
T56	Scope 766 806	indication for dual antiplatelet therapy
T57	Scope 813 838	recent stent implantation
T58	Temporal 860 891	within 90 days before inclusion
T59	Condition 853 859	stroke
T60	Condition 840 852	Debilitating
R25	Has_temporal Arg1:T59 Arg2:T58	
R26	AND Arg1:T59 Arg2:T60	
T61	Temporal 893 901	Previous
T62	Procedure 902 923	intracranial bleeding
R27	Has_temporal Arg1:T62 Arg2:T61	
T63	Drug 940 958	immunosuppressants
T64	Drug 965 977	cyclosporine
T65	Drug 982 992	tacrolimus
*	OR T64 T65
T66	Scope 965 992	cyclosporine and tacrolimus
R28	Subsumes Arg1:T63 Arg2:T66	
T67	Drug 1010 1034	strong CYP3A4-inhibitors
T68	Drug 1041 1053	ketoconazole
T69	Drug 1055 1069	clarithromycin
T70	Drug 1071 1081	nefazodone
T71	Drug 1083 1092	ritonavir
T72	Drug 1096 1106	atazanavir
*	OR T71 T72 T70 T69 T68
T73	Scope 1041 1106	ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir
R29	Subsumes Arg1:T67 Arg2:T73	
T74	Non-query-able 1109 1209	Any condition that in the opinion of the investigator may interfere with adherence to trial protocol
